These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35892835)

  • 1. Combinations using checkpoint blockade to overcome resistance.
    Morganti S; Curigliano G
    Ecancermedicalscience; 2020; 14():1148. PubMed ID: 33574893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bifidobacterium modulation of tumor immunotherapy and its mechanism.
    Pei B; Peng S; Huang C; Zhou F
    Cancer Immunol Immunother; 2024 Apr; 73(5):94. PubMed ID: 38564002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immune Cells and Immunotherapy in Multiple Myeloma.
    Radhakrishnan V; Golla U; Kudva AK
    Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
    Sato K; Miura K; Tamori S; Akimoto K
    Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy.
    Park SM; Kim YJ; Lee JY
    Cancer Med; 2024 Apr; 13(7):e7142. PubMed ID: 38545845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses.
    Kamrani A; Nasiri H; Hassanzadeh A; Ahmadian Heris J; Mohammadinasab R; Sadeghvand S; Sadeghi M; Valedkarimi Z; Hosseinzadeh R; Shomali N; Akbari M
    Cell Commun Signal; 2024 Jan; 22(1):56. PubMed ID: 38243252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.
    Yao L; Wang Q; Ma W
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Diseases Associated with Aging: Molecular Mechanisms and Treatment Strategies.
    Kim ME; Lee JS
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Pathway Expression in Lymphocyte Subpopulations in Patients with Common Variable Immunodeficiency and Chronic Lymphocytic Leukemia.
    Mertowska P; Mertowski S; Smolak K; Kita A; Kita G; Guz K; Pasiarski M; Grywalska E
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Microbiome in Gastric Cancer: Assessing Potential Implications and Contextualizing Microorganisms beyond
    Shin WS; Xie F; Chen B; Yu J; Lo KW; Tse GMK; To KF; Kang W
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice.
    Confino H; Sela Y; Epshtein Y; Malka L; Goldshtein M; Chaisson S; Lisi S; Avniel A; Monson JM; Dirbas FM
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
    Lepper A; Bitsch R; Özbay Kurt FG; Arkhypov I; Lasser S; Utikal J; Umansky V
    Oncoimmunology; 2023; 12(1):2247303. PubMed ID: 37593676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural-Product-Derived Adjunctive Treatments to Conventional Therapy and Their Immunoregulatory Activities in Triple-Negative Breast Cancer.
    Kan LL; Chan BC; Leung PC; Wong CK
    Molecules; 2023 Aug; 28(15):. PubMed ID: 37570775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events.
    Meybodi SM; Farasati Far B; Pourmolaei A; Baradarbarjastehbaf F; Safaei M; Mohammadkhani N; Samadani AA
    Med Oncol; 2023 Jul; 40(8):243. PubMed ID: 37453930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immune escape: the role of antigen presentation machinery.
    Kallingal A; Olszewski M; Maciejewska N; Brankiewicz W; Baginski M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):8131-8141. PubMed ID: 37031434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer.
    Benelli R; Zocchi MR; Poggi A
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in Cancer Therapy-How Can We Improve Clinical Benefits?
    Baxevanis CN
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications.
    Wu P; Han J; Gong Y; Liu C; Yu H; Xie N
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?
    Lao Y; Shen D; Zhang W; He R; Jiang M
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892835
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.